Amgen INC Form 4 insider transactions

Amgen's Senior Vice President of Business Development, Rachna Khosla, reported the sale of 1,500 shares of common stock at a price of $289.68 per share, effective June 5, 2025.

Amgen Inc. Director Amy E. Miles acquired 809 shares of common stock on May 23, 2025, through the company's Director Incentive Program, increasing her total beneficial ownership to 4,842 shares.

Amgen Inc. Director Ellen Jamison Kullman reported the acquisition of 809 shares of common stock on May 23, 2025, as part of the company's Director Incentive Program.

Amgen Inc. Director Mary E. Klotman has acquired 809 shares of common stock through a Restricted Stock Unit (RSU) grant, increasing her beneficial ownership to 1,528 shares.

Amgen Inc. Director Omar Ishrak reported the acquisition of 809 shares of common stock through a Restricted Stock Unit grant, increasing his beneficial ownership to 6,084.4994 shares.

Amgen Director Tyler Jacks reported the acquisition of 809 shares of common stock on May 23, 2025, through the vesting of Restricted Stock Units under the company's Director Incentive Program.

Amgen Inc. Director Charles M. Holley has increased his direct beneficial ownership of company common stock by 809 shares through a Restricted Stock Unit grant and Dividend Equivalents, effective May 23, 2025.

Amgen Inc. Director Greg C. Garland acquired 809 shares of common stock on May 23, 2025, through the immediate vesting of Restricted Stock Units, increasing his total beneficial ownership to 13,183 shares.

Amgen Inc. Director Robert Eckert has reported the acquisition of 809 shares of common stock, increasing his total beneficial ownership to 25,027 shares, as part of the company's Director Incentive Program.

Amgen Inc. Director Brian Druker reported the acquisition of 809 shares of common stock on May 23, 2025, primarily through the vesting of Restricted Stock Units (RSUs) and Dividend Equivalents, increasing his total beneficial ownership to 7,569 shares.

Amgen Inc. Director Michael V. Drake has acquired 809 shares of common stock through a Restricted Stock Unit (RSU) grant, increasing his beneficial ownership to 4,546.5983 shares.

Amgen Inc. Director Wanda M. Austin has reported the acquisition of 809 shares of common stock through the vesting of Restricted Stock Units, increasing her beneficial ownership to 7,353 shares.

Amgen's CEO, Robert Bradway, reports the acquisition of restricted stock units and non-qualified stock options, along with adjustments to his holdings of common stock.

EVP of Operations at Amgen, Esteban Santos, reports acquisition of stock and option awards.

EVP & Chief Technology Officer of Amgen, David M. Reese, reports the acquisition of common stock and non-qualified stock options.

Derek Miller, SVP of Human Resources at Amgen, reports the acquisition of restricted stock units and non-qualified stock options, along with dividend equivalents.

Rachna Khosla, SVP of Business Development at Amgen, reports the acquisition of restricted stock units and non-qualified stock options.

Nancy A. Grygiel, SVP & CCO of Amgen Inc., reports acquisition of restricted stock units and non-qualified stock options, as well as transactions in company stock through the 401(k) plan.

Peter H. Griffith, EVP & CFO of Amgen Inc., reports the acquisition of stock options and restricted stock units (RSUs) in a recent SEC Form 4 filing.

Jonathan P. Graham, EVP & General Counsel & Secretary of Amgen Inc., reports the acquisition of common stock and stock options.

Murdo Gordon, EVP of Global Commercial Operations at Amgen, reports the acquisition of common stock and stock options, including restricted stock units, dividend equivalents, and non-qualified stock options.

Matthew C. Busch, VP of Finance & CAO at Amgen, reports acquisition of common stock and stock options.

James E. Bradner, EVP, R&D, & Chief Scientific Officer of Amgen, reports the acquisition of stock and option awards.

Director Charles M. Holley reports acquiring Amgen common stock through restricted stock units and dividend equivalents.

Director Omar Ishrak reports acquiring Amgen common stock through vested Restricted Stock Units (RSUs) and dividend equivalents.

Director Michael V. Drake reports acquiring Amgen common stock through vested Restricted Stock Units (RSUs) and dividend equivalents.

Esteban Santos, EVP of Operations at Amgen, reports the disposal of shares to cover tax obligations related to vested restricted stock units.

EVP & Chief Technology Officer of Amgen, David M. Reese, reports disposals of common stock to cover tax obligations.

Derek Miller, SVP of Human Resources at Amgen, reported the disposal of common stock to cover tax obligations.

Rachna Khosla, SVP of Business Development at Amgen, reported disposing of shares to cover tax obligations related to vested restricted stock units.